DeepMed Research

UNIVERSITY OF SYDNEY

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Established: 1850-01-01

Employees: -

Market Cap: -

Website: https://www.sydney.edu.au/

Clinical Trials

Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema

Not Applicable

Conditions: Macula Edema
Retinal Vein Occlusion

Interventions: Device: Ellex Integre NIR laser

First Posted Date: 2021-04-19

Last Posted Date: 2021-04-19

Lead Sponsor: University of Sydney

Target Recruit Count: 14

Registration Number: NCT04847869

Locations: 🇦🇺
Macular Research Group, Save Sight Institute, The University of Sydney, Sydney, New South Wales, Australia

The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers

Phase 1

Completed

Conditions: SARS-CoV2 COVID-19

Interventions: Biological: COVIGEN C19 2.0 mg IM or Placebo IM
Biological: COVIGEN C20 1.0mg vaccine ID
Biological: COVIGEN C19 0.8 mg ID or Placebo ID
Biological: COVIGEN C19 4.0 mg IM or Placebo IM

First Posted Date: 2021-02-08

Last Posted Date: 2023-10-30

Lead Sponsor: University of Sydney

Target Recruit Count: 68

Registration Number: NCT04742842

Locations: 🇦🇺
Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Adelaide, South Australia, Australia
🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
🇦🇺
Wesfarmers Centre of Vaccines and Infectious Diseases Telethon Kids Institute, Perth, Western Australia, Australia

Nano-X Image Guidance: CBCT With Gravity-induced Motion

Early Phase 1

Not yet recruiting

Conditions: Cancer

Interventions: Device: Nano-X Patient Rotation System
Radiation: Conventional CBCT scan
Other: Psychometrically validated questionnaires

First Posted Date: 2020-07-27

Last Posted Date: 2024-06-06

Lead Sponsor: University of Sydney

Target Recruit Count: 30

Registration Number: NCT04488224

Investigation of Respiratory-related Tumour Motion in Liver Cancer Patients Undergoing SBRT Using Audiovisual Biofeedback

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Device: Breathe Well

First Posted Date: 2020-03-26

Last Posted Date: 2025-04-04

Lead Sponsor: University of Sydney

Target Recruit Count: 5

Registration Number: NCT04323618

Surface Monitoring Technology to Remove The Mask - Stage 1

Not Applicable

Recruiting

Conditions: Head and Neck Cancer
Radiation Therapy Complication
Anxiety

Interventions: Device: Mask-free surface monitoring

First Posted Date: 2020-02-12

Last Posted Date: 2024-07-09

Lead Sponsor: University of Sydney

Target Recruit Count: 20

Registration Number: NCT04266223

Locations: 🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

Phase 2

Active, not recruiting

Conditions: Glioblastoma Multiforme

Interventions: Drug: Nivolumab
Drug: Temozolomide

First Posted Date: 2019-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: University of Sydney

Target Recruit Count: 103

Registration Number: NCT04195139

Locations: 🇦🇺
Gosford Hospital, Gosford, New South Wales, Australia
🇦🇺
Icon Cancer Centre, South Brisbane, Queensland, Australia
🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

and more 17 locations

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Darolutamide
Drug: Placebo oral tablet
Drug: Luteinizing Hormone-Releasing Hormone Analog
Radiation: External Beam Radiotherapy

First Posted Date: 2019-10-23

Last Posted Date: 2023-07-28

Lead Sponsor: University of Sydney

Target Recruit Count: 1100

Registration Number: NCT04136353

Locations: 🇨🇦
Regional Health Authority B, Zone 2 Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦
Ottawa Hospital Research Institute, Toronto, Ontario, Canada
🇨🇦
Odette Cancer Centre - Sunnybrook Hospital, Toronto, Ontario, Canada

and more 90 locations

Observational Study of Cardiovascular Disease.

Terminated

Conditions: Cardiovascular Morbidity
Cardiovascular Diseases
Coronary Heart Disease
Low-density-lipoprotein-type

First Posted Date: 2019-10-16

Last Posted Date: 2024-04-08

Lead Sponsor: University of Sydney

Target Recruit Count: 1137

Registration Number: NCT04128475

Locations: 🇺🇸
TIMI Study Group, Boston, Massachusetts, United States
🇳🇴
Oslo University Hospital, Nydalen, Oslo, Norway
🇬🇧
Imperial College London, London, United Kingdom

Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging

Not Applicable

Recruiting

Conditions: Lung Cancer

Interventions: Device: Markerless Image Guidance

First Posted Date: 2019-09-11

Last Posted Date: 2024-01-11

Lead Sponsor: University of Sydney

Target Recruit Count: 30

Registration Number: NCT04086082

Locations: 🇦🇺
Alfred Health, Melbourne, Victoria, Australia

Adaptive CT Acquisition for Personalised Thoracic Imaging

Completed

Conditions: Cancer, Lung

Interventions: Device: 4DCBCT images

First Posted Date: 2019-08-28

Last Posted Date: 2021-05-19

Lead Sponsor: University of Sydney

Target Recruit Count: 30

Registration Number: NCT04070586

Locations: 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy